These minimal-sized binders are very robust and bind the antigen with high affinity in a monomeric state. diabody. We showed the ability of diabody to recognition of VEGFR2 on the cell surface by FACS. Diabodies can be produced in the low-cost prokaryotic expression system, so they are suitable molecules for diagnostic and therapeutic issues. Keywords:Diabody, Nanobody, vascular endothelial growth factor recepror-2 == INTRODUCTION == Antibodies and their products have been used as versatile tools in many areas. Their applications in fundamental research work and also in diagnosis and therapy have been reported many times. For instance, utilization of antibodies as drug delivery vehicles, or in cancer therapy as triggers for immune response can be mentioned as some successful achievements.[1] High-yield production, solubility, stability, and small size are critical factors. Regarding this, many attempts to reduce the size of the conventional heterotetrameric IgG molecule (MW; 160 kDa), while retaining its antigen-binding properties, have been conducted. This resulted in a series of antibody fragment constructs, such as Fabs, Fvs, scFvs, dsFvs, and even single-domain VHs, which can be expressed inEscherichia coli, yeast or myeloma cells.[2] Camelids generate antibodies that formed by two heavy chains, but no light chains. These immunoglobulins (MW; 95 kDa), referred to heavy-chain antibodies, constitute a major fraction of the functional Domatinostat tosylate antibodies in camels (up to 50% in camels). Refined structural changes in the variable domain of the naturally occurring heavy-chain antibodies (named as VHH or Nanobody) compensate for the absence of light chain variable domain.[3,4] Vascular endothelial growth factor (VEGF) and its receptors; VEGFR-1, 2, 3, especially VEGFR2, play particularly an important role in angiogenesis under both physiological and pathological conditions.[5,6] Domatinostat tosylate VEGFR2 seems to be the major transducer of VEGF signals in endothelial cells that result in cell proliferation, migration, differentiation, tube formation, increasing vascular permeability, and maintenance of the Mouse monoclonal to IL-16 vessels.[7] Thus, some therapies based on antibody could be one of the possible and also effective therapeutic strategies for inhibition of tumor growth and metastasis by blocking angiogenesis pathways in affected tissues through inhibition of VEGF or its receptor signaling system.[8] Our research group has previously characterized a high affinity VEGFR2-specific Nanobody, andin vitrostudies demonstrated the ability of this Domatinostat tosylate Nanobody, termed 3VGR19, to bind VEGFR2 on the cell surface.[9] In this study, we show that the affinity of binding to antigen does not change by constructing the diabody. This study is an introduction toin vivotests to evaluate the performance of this antibody. == MATERIALS AND METHODS == == Diabody gene construction == The VEGFR2-specific Nanobody gene[9] was amplified from pHEN-4 plasmid, which contains VEGFR2-specific Nanobody (3VGR19) gene by using forward, A6E (5-GAT GTG CAG CTG CAG GAG TCT GGR GGA GG-3), and reverse 38 (5-GGA CTA GTG CGG CCG CTG GAG ACG GTG ACC TGG GT-3) primers and subcloned into the pHEN6C vector in PstI and BstEII restriction sites. For diabody construction, the 3VGR19 gene amplified again with BiNb-Sense (5-GCC CAG CCG GCC ATG GCC CAG KTG CAG CTA CAG GAG TCN GGN GG-3) and BiNb-Llama-IgG2C-hinge (5-GCC TGA TTC CTG CAG CTG CAC CTG TGC CAT TGG AGC TTT GGG AGC TTT GGA GCT GGG GTC TTC GCT GTG GTG CGC TGA GGA GAC GGT GAC CTG GGT-3) primers. The PCR product was purified and digested with PstI and NcoI and ligated with pHEN6C vector that contains the first Nanobody.[9] Furthermore, the linker sequence of hinge region of Llama IgG2 was added to the respected construct with BiNb-Llama-IgG2C-hinge primer. The resulting plasmid was confirmed by sequencing and named as pHEN6c-3VGR19-Dia. == Expression and purification == The recombinant plasmid pHEN6C-3VGR19-Dia was transformed in competent WK-6 E. coli cells and the cells were plated on LuriaBertani (LB) agar plates supplemented with 1% glucose and 100 g/mL ampicillin. After an overnight incubation, fresh colonies inoculated in 5 mL terrific broth (TB) medium with additional 20% glucose and 2 mM MgCl2, then scaled up bacterial culture from 5 mL to 5 L in shaker incubator at 37C until the OD 600 reached to 0.6 and then induced with 1 mM isopropyl-D-1-thiogalactopyranoside (IPTG). After induction, cells were allowed to grow and express for 1216 h.